TCRRライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (1 6月 2023 @ 05:00):

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer...

Stats
本日の出来高	3.75M
平均出来高	325 040
時価総額	58.11M
EPS	$0 ( 2024-03-21 )
次の収益日	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.352
ATR14	$0.105 (7.09%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-01	Tang Kevin C	Sell	4 394 800	Common Stock
2023-06-01	Ubs Oncology Impact Fund L.p.	Sell	3 370 982	Common Stock
2023-06-01	Mpm Sunstates Fund, L.p.	Sell	4 158 964	Common Stock
2023-06-01	Mpm Bioventures 2014, L.p.	Sell	4 158 964	Common Stock
2023-06-01	Gadicke Ansbert	Sell	3 370 982	Common Stock

INSIDER POWER
-89.62
Last 99 transactions
Buy: 1 629 400 \| Sell: 23 030 678

ボリューム相関

長: 0.06 (neutral)

短: -0.70 (moderate negative)

Signal:(27.338) Neutral

TCR2 Therapeutics Inc 相関

10 最も正の相関
RMRM	0.89
GAINL	0.889
APOP	0.884
PAIC	0.864
TDAC	0.851
SPRT	0.842
ISNS	0.833
TLGT	0.82
SVAC	0.816

10 最も負の相関
BOCH	-0.936
BNIXU	-0.929
MMAC	-0.891
NETE	-0.87
SHSP	-0.865
AMRB	-0.841
DSPG	-0.816

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

TCR2 Therapeutics Inc 相関 - 通貨/商品

-0.14
( neutral )

0.52
( weak )

0.00
( neutral )

0.21
( neutral )

0.63
( weak )

0.04
( neutral )

TCR2 Therapeutics Inc 財務諸表

Annual	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-3.93

FY	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-3.93

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-3.57

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-2.40

Financial Reports:

No articles found.

TCR2 Therapeutics Inc

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.